Publications + Posters

 |  AACR

April 2025

TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of solid tumors with MTAP loss

Kimberly J. Briggs, et al.

 |  AACR

April 2025

Genetic and pharmacological disruption of the HBS1L/PELO complex impairs mRNA homeostasis and leads to in vivo tumor regressions in FOCAD-deleted cancers

Lauren Martires, et al.

 |  AACR

April 2025

Evaluation of the impact of homozygous MTAP truncations on the clinical activity of MTA-cooperative PRMT5 inhibitors

Kimberly J. Briggs, et al.

 |  AACR

April 2025

TNG462, an MTA-cooperative PRMT5 inhibitor, demonstrates strong efficacy in combination with clinically relevant targeted therapies in MTAP-null preclinical models

Minjie Zhang, et al.

 |  AACR

April 2025

Preclinical evaluation of CNS drug penetration of a novel series of MTAP-selective PRMT5 inhibitors including TNG456

Alice Tsai, et al.